查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1401898

2030年全球黑色素瘤诊断与治疗市场预测：按癌症类型、诊断、治疗、应用和地区进行全球分析

Melanoma Diagnostics and Therapeutics Market Forecasts to 2030 - Global Analysis By Cancer Type, By Diagnosis (Dermatoscopy, Blood Tests, Computed Tomography Scan and Other Diagnosis), Therapy, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球黑色素瘤诊断和治疗市场在预测期内将以 17.1% 的复合年增长率成长。

黑色素瘤诊断涉及识别和评估黑色素细胞病变以诊断皮肤癌。技术包括皮肤镜检查、切片检查和分析基因突变的分子测试。黑色素瘤的治疗包括手术切除、免疫治疗、标靶治疗和化疗。查核点抑制剂等免疫疗法和针对特定基因变化的标靶治疗正在发挥重要作用。早期检测和个体化治疗策略对于黑色素瘤的治疗至关重要。

据美国癌症协会称，预计2022年美国将新增约99,780例黑色素瘤病例，同年将有约7,650人死于黑色素瘤。

黑色素瘤增加

长期日晒、生活方式改变和遗传倾向等因素导致全球黑色素瘤病例增加。发病率的迅速增加需要先进的诊断工具和治疗性介入。宣传宣传活动和定期皮肤检查的增加进一步增加了对早期发现和有效治疗的需求。该行业对这些日益增长的健康问题的回应包括诊断和治疗方面的持续创新，其中黑色素瘤盛行率的上升是市场扩张的关键驱动力。

治疗费用高

与黑色素瘤的创新诊断、标靶治疗和免疫疗法相关的成本可能很高，限制了某些患者群体获得治疗的机会。这种财务障碍可能会阻碍及时和最佳的治疗并影响患者的治疗结果。此外，高成本对医疗保健系统造成负担，给个人和付款人带来经济挑战，并可能影响整体市场成长。

诊断技术的进步

高解析度成像技术、液体活检和分子分析等创新诊断工具可以实现黑色素瘤的早期、准确检测。这些技术提高的敏感性和特异性有助于及时干预并改善患者的治疗结果。此外，非侵入性和准确的诊断方法符合个人化医疗的成长趋势，并促进量身定制的治疗方法。这些技术进步不仅有助于早期诊断，而且在监测治疗反应和疾病进展方面发挥重要作用。

专门医疗保健中心的数量有限

专业医疗中心数量有限是黑色素瘤诊断和治疗市场的主要威胁。黑色素瘤通常需要专业知识才能进行准确的诊断和量身定制的治疗计划。缺乏此类中心会导致诊断延误，阻碍获得先进的治疗性介入，并限制患者的治疗效果。此外，患者可能面临地理障碍，特别是在服务不足的地区，这会影响及时获得关键诊断服务和尖端治疗方法，导致市场扩张受到限制。

COVID-19 的影响：

COVID-19大流行对黑色素瘤诊断和治疗市场产生了重大影响。医疗保健服务的中断、资源的重新调整以及患者对前往医疗保健机构的恐惧导致黑色素瘤诊断和治疗的延误。然而，这场大流行凸显了创新远距医疗解决方案的重要性，并加速了远端医疗和数位医疗技术的采用。

预计血液检测领域在预测期内将是最大的。

由于血液检测的非侵入性和对黑色素瘤相关生物标记的有效检测，预计将成为黑色素瘤诊断市场中最大的部分。血液检测为早期检测提供了一种方便易行的方法，可以及时进行干预。液体活检技术的进步和循环肿瘤标记的鑑定正在促进该领域的兴起。随着对准确和微创诊断方法的需求增加，血液检测领域预计将占据主导地位，以满足有效黑色素瘤检测和监测日益增长的需求。

预计放射治疗产业在预测期内复合年增长率最高。

预计放射线治疗领域黑色素瘤诊断和治疗市场将出现良好成长。这种增长是由于越来越多地采用放射疗法作为黑色素瘤的有效治疗选择。强度调控放射治疗(IMRT) 和立体定位放射线手术等放射治疗技术的进步有助于提高准确性并减少副作用。人们越来越重视将放射治疗纳入综合治疗策略的联合治疗，这也推动了放射治疗的需求。

占有率最大的地区

由于先进的医疗基础设施、黑色素瘤患者的高盛行率以及活跃的研发活动，预计北美将在黑色素瘤诊断和治疗市场中占据最大的市场占有率。此外，意识的提高、创新诊断技术的早期采用以及主要市场参与者的存在也有助于北美的主导地位。此外，有利的报销政策、积极的法规环境以及对个人化医疗的关注进一步支持了该地区的市场领导地位。

复合年增长率最高的地区：

预计亚太地区黑色素瘤诊断和治疗市场的成长率最高。这是由于人们认识的提高、医疗基础设施的改善、可支配收入的增加以及人口高龄化导致黑色素瘤发病率上升。此外，该地区主要经济体医疗保健技术的进步、研究倡议的扩大以及对个人化医疗的关注正在进一步推动对先进诊断和治疗的需求。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球黑色素瘤诊断与治疗市场：按癌症类型

  • 末期雀斑样黑色素瘤
  • 黑色素瘤 黑色素瘤
  • 香菇黑色素瘤
  • 结节性黑色素瘤
  • 表浅黑色素瘤
  • 其他类型的癌症

第六章全球黑色素瘤诊断与治疗市场：依诊断分类

  • 皮肤镜检查
  • 验血
  • 电脑断层扫描 (CT) 扫描
  • 前哨淋巴结活检
  • 超音波
  • X射线
  • 其他诊断

第七章全球黑色素瘤诊断与治疗市场：依治疗分类

  • 化疗
  • 生物疗法
  • 免疫疗法
  • 放射线治疗
  • 标靶治疗
  • 其他治疗

第八章全球黑色素瘤诊断与治疗市场：依应用分类

  • 诊断中心
  • 医院
  • 医疗机构
  • 其他用途

第九章全球黑色素瘤诊断与治疗市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司简介

  • Abbott Diagnostics
  • Agilent Technologies
  • Amgen, Inc.
  • AstraZeneca
  • Biomerieux SA
  • Bristol Myers Squibb
  • Caliber Imaging & Diagnostics, Inc.
  • Canfield Scientific, Inc.
  • Dermlite
  • DermTech
  • Eli Lilly and Company
  • Roche Holding AG
  • GlaxoSmithKline PLC
  • Merck & Co., Inc
  • Novartis AG
  • Pfizer, Inc.
  • Qiagen
  • Sanofi
Product Code: SMRC24418

According to Stratistics MRC, the Global Melanoma Diagnostics and Therapeutics Market is growing at a CAGR of 17.1% during the forecast period. Melanoma diagnostics involve the identification and assessment of melanocytic lesions to diagnose skin cancer. Techniques include dermoscopy, biopsy, and molecular testing to analyze genetic mutations. Therapeutics for melanoma comprise surgical excision, immunotherapy, targeted therapy, and chemotherapy. Immunotherapies like checkpoint inhibitors and targeted therapies addressing specific genetic alterations play a crucial role. Early detection and personalized treatment strategies are pivotal in managing melanoma.

According to the American Cancer Society, about 99,780 new melanomas will be diagnosed in the United States in 2022, and around 7,650 people are expected to die of melanoma in the same year.

Market Dynamics:

Driver:

Rising incidence of melanoma

Factors such as prolonged sun exposure, changing lifestyles, and genetic predispositions contribute to a rising number of melanoma cases globally. This surge in incidence necessitates advanced diagnostic tools and therapeutic interventions. Increased awareness campaigns and routine skin screenings further amplify the demand for early detection and effective treatments. The industry's response to this growing health concern involves continuous innovation in diagnostics and therapeutics, positioning the rising incidence of melanoma as a crucial driver fueling market expansion.

Restraint:

High treatment costs

The expenses associated with innovative diagnostics, targeted therapies, and immunotherapies for melanoma can be substantial, limiting accessibility for a portion of the patient population. This financial barrier hampers timely and optimal treatment, potentially impacting patient outcomes. Additionally, high costs may strain healthcare systems and result in economic challenges for both individuals and payers, impacting overall market growth.

Opportunity:

Advancements in diagnostic technologies

Innovative diagnostic tools, such as high-resolution imaging techniques, liquid biopsy assays, and molecular profiling, enable earlier and more accurate detection of melanoma. The enhanced sensitivity and specificity of these technologies contribute to timely interventions, improving patient outcomes. Moreover, non-invasive and precise diagnostic methods align with the growing trend of personalized medicine, facilitating tailored treatment approaches. These technological advancements not only aid in early diagnosis but also play a crucial role in monitoring treatment response and disease progression.

Threat:

Limited availability of specialized healthcare centers

The limited availability of specialized healthcare centers represents a significant threat to the melanoma diagnostics and therapeutics market. Melanoma often requires specialized expertise for accurate diagnosis and tailored treatment plans. The scarcity of such centers can lead to delays in diagnosis, hinder access to advanced therapeutic interventions, and limit patient outcomes. Additionally, patients may face geographical barriers, particularly in underserved regions, impacting timely access to crucial diagnostic services and cutting-edge therapies, which limits market expansion.

COVID-19 Impact:

The COVID-19 pandemic significantly impacted the melanoma diagnostics and therapeutics market. Disruptions in healthcare services, reprioritization of resources, and patients' concerns about visiting healthcare facilities led to delays in melanoma diagnosis and treatment. However, the pandemic underscored the importance of innovative and remote healthcare solutions, accelerating the adoption of telemedicine and digital health technologies.

The blood tests segment is expected to be the largest during the forecast period

The blood testing segment is expected to be the largest in the melanoma diagnostics market due to its non-invasive nature and efficiency in detecting biomarkers associated with melanoma. Blood-based tests offer a convenient and accessible means for early detection, enabling timely intervention. Advancements in liquid biopsy technologies and the identification of circulating tumor markers in blood contribute to the segment's prominence. As the demand for accurate, less invasive diagnostic methods grows, the blood testing segment is anticipated to dominate, catering to the increasing need for effective melanoma detection and monitoring.

The radiotherapy segment is expected to have the highest CAGR during the forecast period

The radiotherapy segment is projected to achieve lucrative growth in the melanoma diagnostics and therapeutics market. This growth is attributed to the increasing adoption of radiotherapy as an effective treatment option for melanoma. Technological advancements in radiotherapy techniques, including intensity-modulated radiation therapy (IMRT) and stereotactic radiosurgery, contribute to enhanced precision and reduced side effects. The growing emphasis on combination therapies, where radiotherapy is integrated into comprehensive treatment strategies, further propels the demand for radiotherapy.

Region with largest share:

North America is poised to command the largest market share in the melanoma diagnostics and therapeutics market due to its advanced healthcare infrastructure, a high prevalence of melanoma cases, and robust research and development activities. Moreover, increasing awareness, early adoption of innovative diagnostic technologies, and the presence of key market players contribute to North America's dominant position. Additionally, favorable reimbursement policies, a proactive regulatory environment, and a focus on personalized medicine further drive the region's leadership in the market.

Region with highest CAGR:

The Asia Pacific region is poised to experience the highest growth rate in the melanoma diagnostics and therapeutics market due to increasing awareness, improving healthcare infrastructure, rising disposable income, and a growing aging population that contribute to a higher prevalence of melanoma cases. Additionally, advancements in healthcare technologies, expanding research initiatives, and a focus on personalized medicine in key economies within the region further drive the demand for advanced diagnostics and therapeutics.

Key players in the market:

Some of the key players in Melanoma Diagnostics And Therapeutics Market include Abbott Diagnostics, Agilent Technologies, Amgen, Inc., AstraZeneca, Biomerieux SA, Bristol Myers Squibb, Caliber Imaging & Diagnostics, Inc., Canfield Scientific, Inc., Dermlite, DermTech, Eli Lilly and Company, Roche Holding AG, GlaxoSmithKline PLC, Merck & Co., Inc, Novartis AG, Pfizer, Inc., Qiagen and Sanofi.

Key Developments:

In November 2023, The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.

In November 2023, Amgen announced new data reinforcing the safety and efficacy of Repatha® (evolocumab) from the FOURIER Open Label Extension (OLE) [FOURIER-OLE] trial at the American Heart Association (AHA) Scientific Sessions 2023 in Philadelphia. These presentations will focus on the reduction of a known cardiovascular disease (CVD) risk factor, LDL "bad" cholesterol (LDL-C). Amgen will also present new research from the Phase 2 OCEAN(a)-DOSE study of its investigational small interfering RNA (siRNA) olpasiran that will focus on a primarily genetically determined and presumed independent CVD risk factor, lipoprotein(a) [Lp(a)].

In October 2023, Novartis, a global leader in immuno-dermatology and rheumatology, announced that the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. Cosentyx is the only FDA-approved fully human biologic that directly inhibits interleukin-17A (IL-17A), a cytokine believed to be involved in the inflammation of HS.

Cancer Types Covered:

  • Acral Lentiginous Melanoma
  • Amelanotic Melanoma
  • Lentigno gna Melanoma
  • Nodular Melanoma
  • Superficial Spreading Melanoma
  • Other Cancer Types

Diagnosis Covered:

  • Dermatoscopy
  • Blood Tests
  • Computed Tomography (CT) Scan
  • Sentinel Lymph Node Biopsy
  • Ultrasound
  • X-Rays
  • Other Diagnosis

Therapies Covered:

  • Chemotherapy
  • Biological Therapy
  • Immune Therapy
  • Radiotherapy
  • Targeted Therapy
  • Other Therapies

Applications Covered:

  • Diagnostic Centers
  • Hospitals
  • Medical Institutions
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Melanoma Diagnostics and Therapeutics Market, By Cancer Type

  • 5.1 Introduction
  • 5.2 Acral Lentiginous Melanoma
  • 5.3 Amelanotic Melanoma
  • 5.4 Lentigno gna Melanoma
  • 5.5 Nodular Melanoma
  • 5.6 Superficial Spreading Melanoma
  • 5.7 Other Cancer Types

6 Global Melanoma Diagnostics and Therapeutics Market, By Diagnosis

  • 6.1 Introduction
  • 6.2 Dermatoscopy
  • 6.3 Blood Tests
  • 6.4 Computed Tomography (CT) Scan
  • 6.5 Sentinel Lymph Node Biopsy
  • 6.6 Ultrasound
  • 6.7 X-Rays
  • 6.8 Other Diagnosis

7 Global Melanoma Diagnostics and Therapeutics Market, By Therapy

  • 7.1 Introduction
  • 7.2 Chemotherapy
  • 7.3 Biological Therapy
  • 7.4 Immune Therapy
  • 7.5 Radiotherapy
  • 7.6 Targeted Therapy
  • 7.7 Other Therapies

8 Global Melanoma Diagnostics and Therapeutics Market, By Application

  • 8.1 Introduction
  • 8.2 Diagnostic Centers
  • 8.3 Hospitals
  • 8.4 Medical Institutions
  • 8.5 Other Applications

9 Global Melanoma Diagnostics and Therapeutics Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Abbott Diagnostics
  • 11.2 Agilent Technologies
  • 11.3 Amgen, Inc.
  • 11.4 AstraZeneca
  • 11.5 Biomerieux SA
  • 11.6 Bristol Myers Squibb
  • 11.7 Caliber Imaging & Diagnostics, Inc.
  • 11.8 Canfield Scientific, Inc.
  • 11.9 Dermlite
  • 11.10 DermTech
  • 11.11 Eli Lilly and Company
  • 11.12 Roche Holding AG
  • 11.13 GlaxoSmithKline PLC
  • 11.14 Merck & Co., Inc
  • 11.15 Novartis AG
  • 11.16 Pfizer, Inc.
  • 11.17 Qiagen
  • 11.18 Sanofi

List of Tables

  • Table 1 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 3 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Acral Lentiginous Melanoma (2021-2030) ($MN)
  • Table 4 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Amelanotic Melanoma (2021-2030) ($MN)
  • Table 5 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Lentigno gna Melanoma (2021-2030) ($MN)
  • Table 6 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Nodular Melanoma (2021-2030) ($MN)
  • Table 7 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Superficial Spreading Melanoma (2021-2030) ($MN)
  • Table 8 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 9 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Diagnosis (2021-2030) ($MN)
  • Table 10 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Dermatoscopy (2021-2030) ($MN)
  • Table 11 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 12 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Computed Tomography (CT) Scan (2021-2030) ($MN)
  • Table 13 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Sentinel Lymph Node Biopsy (2021-2030) ($MN)
  • Table 14 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Ultrasound (2021-2030) ($MN)
  • Table 15 Global Melanoma Diagnostics and Therapeutics Market Outlook, By X-Rays (2021-2030) ($MN)
  • Table 16 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Other Diagnosis (2021-2030) ($MN)
  • Table 17 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Therapy (2021-2030) ($MN)
  • Table 18 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 19 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Biological Therapy (2021-2030) ($MN)
  • Table 20 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Immune Therapy (2021-2030) ($MN)
  • Table 21 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Radiotherapy (2021-2030) ($MN)
  • Table 22 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Targeted Therapy (2021-2030) ($MN)
  • Table 23 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Other Therapies (2021-2030) ($MN)
  • Table 24 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Application (2021-2030) ($MN)
  • Table 25 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 26 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 27 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Medical Institutions (2021-2030) ($MN)
  • Table 28 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.